MSH2 and cancer: The group of MLH1 carriers had the highest proportion of participants with a family history of cancer at 23% (n = 5), followed by the group of MSH6 carriers at 20% (n = 4), while the MSH2 group had the lowest at 13% (n = 6) (Table 2).